Tolmar is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $3.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Tolmar's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Invega Sustenna | Johnson & Johnson | Generic | 2031 | Filed; consent judgment May 2026 | $3.8B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Tolmar's share of it.